

BioSpect

the business of Bio

24 years of leveraging the business of Bio
www.biospectrumindia.com

Fatty Liver Disease Management: Antifibrotic Treatment, Disease Staging and Transplant Eligibility

14 October 2026 | Views | By Ankit Kankar | ankit.kankar@mmactiv.com

Fatty liver disease is common, but it needs timely attention when inflammation and scarring begin. Non-Alcoholic Steatohepatitis (NASH), now also known as Metabolic Dysfunction-Associated Steatohepatitis (MASH), can progress silently over time. Many patients do not notice symptoms until the liver has already developed significant damage.



For patients in Mumbai who are being evaluated for advanced fibrosis, cirrhosis or possible transplant needs, choosing a suitable [liver transplant hospital in Mumbai](#) can support timely staging, specialist review and long-term treatment planning. Understanding how NASH is assessed, managed and monitored can help patients make informed decisions about their treatment and long-term liver care.

Understanding NASH and Liver Scarring

NASH is a more serious form of fatty liver disease. It occurs when fat builds up in the liver causing inflammation and liver cell injury. Over time, this inflammation can lead to fibrosis, which means scarring in the liver. As fibrosis increases, the liver becomes less flexible and less able to function normally. Advanced fibrosis may progress to cirrhosis. Many patients feel well in the early stages, so screening is important for people with metabolic risk factors.

Risk Factors That Need Screening

Certain health conditions increase the risk of NASH and liver fibrosis. Patients may need screening if they have:

- Type 2 diabetes or insulin resistance
- Obesity, especially around the waist
- High cholesterol or triglycerides
- High blood pressure
- A family history of liver disease

People with these risk factors should discuss liver testing with a doctor. Early assessment helps detect fibrosis before serious complications develop.

Disease Staging and Monitoring

Disease staging tells doctors how much liver scarring is present. Fibrosis is commonly graded from F0 to F4. F0 means no significant fibrosis, while F4 indicates cirrhosis.

Doctors may use different tests to assess fibrosis, such as:

- FibroScan to measure liver stiffness
- Blood-based fibrosis scores
- Liver function tests
- Liver biopsy in selected cases

Accurate staging guides the treatment plan. It also helps decide how often the patient needs follow-up. In many cases, staging is repeated over time to check whether fibrosis is stable, improving or progressing.

How to Slow the Progression of NASH

The main goal of NASH care is to reduce liver inflammation and slow fibrosis progression. Treatment usually focuses on metabolic control because NASH is closely linked with weight, diabetes, cholesterol and blood pressure.

Important steps may include:

- Gradual and sustained weight loss
- Good control of blood sugar
- Management of cholesterol and triglycerides
- Regular physical activity
- Reduced intake of sugary drinks and processed foods
- Avoiding alcohol or limiting it as advised
- Avoiding medicines that may harm the liver

Even modest weight loss can help reduce liver fat. A dietitian may recommend a Mediterranean-style eating pattern, balanced protein intake and reduced sugar consumption. These changes work best when they are steady and realistic.

Antifibrotic and Medical Treatment Options

Medical treatment for NASH is changing. Some newer medicines are designed to reduce liver fat, inflammation or fibrosis in selected patients. Antifibrotic treatment may be considered when fibrosis is moderate to advanced, but the patient has not yet developed cirrhosis.

These medicines are not suitable for everyone. Availability may also depend on local approvals and the patient's clinical condition. A hepatologist will assess fibrosis stage, diabetes status, weight, liver function and other health factors before advising any medical therapy.

Lifestyle management remains the foundation of treatment. Medicines may add support in selected cases, but they do not replace diet, weight control, exercise and regular monitoring.

Transplant Eligibility in Advanced Liver Disease

Some patients may develop advanced cirrhosis despite treatment. A liver transplant may be considered when cirrhosis leads to serious complications or liver failure. This does not mean every patient with cirrhosis needs a transplant. Doctors assess transplant eligibility through liver function, complication history, overall health and scoring systems such as MELD. They also check the heart, kidneys, infections and general fitness before listing a patient. Early referral to a transplant team helps patients understand whether transplant evaluation is needed.

Choosing a Liver Care Centre in Mumbai

NASH and cirrhosis care often need support from several specialists. The [best multi-speciality hospital in Mumbai](#) can bring together hepatology, radiology, endocrinology, nutrition, critical care, and transplant services. Established centres such as Sir H. N. Reliance Foundation Hospital provides care for fatty liver, cirrhosis, liver failure and liver transplantation. This type of coordinated care can help patients move from diagnosis and staging to treatment planning and long-term follow-up. Patients should ask about fibrosis staging tools, transplant evaluation, liver cancer screening, nutrition support and follow-up systems. These details help families understand how the centre manages liver disease over time.

Conclusion

Preventing NASH-related cirrhosis starts with early diagnosis, accurate fibrosis staging and regular monitoring. Treatment is guided by the stage of liver disease and may include lifestyle changes, management of metabolic conditions, antifibrotic therapy in selected patients and transplant evaluation when appropriate. Understanding each stage of the disease helps patients make informed decisions and begin treatment at the right time. For those seeking advanced liver care, choosing a liver transplant hospital in Mumbai with experienced hepatology and transplant teams, comprehensive diagnostic services and long-term follow-up can support effective disease management and improve long-term liver health.